Repligen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Repligen and other ETFs, options, and stocks.

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. 

CEO
Olivier Dominique Loeillot
CEOOlivier Dominique Loeillot
Employees
1,778
Employees1,778
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1981
Founded1981
Employees
1,778
Employees1,778

RGEN Key Statistics

Market cap
9.39B
Market cap9.39B
Price-Earnings ratio
6.49K
Price-Earnings ratio6.49K
Dividend yield
Dividend yield
Average volume
526.42K
Average volume526.42K
High today
$169.56
High today$169.56
Low today
$164.52
Low today$164.52
Open price
$167.49
Open price$167.49
Volume
388.93K
Volume388.93K
52 Week high
$182.52
52 Week high$182.52
52 Week low
$102.97
52 Week low$102.97

Stock Snapshot

As of today, Repligen(RGEN) shares are valued at $166.82. The company's market cap stands at 9.39B, with a P/E ratio of 6491.05.

As of 2026-01-11, Repligen(RGEN) stock has fluctuated between $164.52 and $169.56. The current price stands at $166.82, placing the stock +1.4% above today's low and -1.6% off the high.

The Repligen(RGEN)'s current trading volume is 388.93K, compared to an average daily volume of 526.42K.

In the last year, Repligen(RGEN) shares hit a 52-week high of $182.52 and a 52-week low of $102.97.

In the last year, Repligen(RGEN) shares hit a 52-week high of $182.52 and a 52-week low of $102.97.

RGEN News

Nasdaq 5d
Repligen Board Elects Martin Madaus As Chair

(RTTNews) - Repligen Corp. (RGEN), a life sciences company, on Tuesday announced that its board has elected Martin Madaus as chair of the board, effective March...

Repligen Board Elects Martin Madaus As Chair
TipRanks 5d
Repligen Appoints Martin Madaus as New Board Chair

Claim 70% Off TipRanks Premium Repligen ( (RGEN) ) has provided an update. On January 6, 2026, Repligen Corporation announced that its board has elected indep...

TipRanks 5d
Repligen executive chair Tony Hunt to retire, Martin Madaus to succeed

Repligen (RGEN) Corporation announced that the Board has elected Dr. Martin Madaus as Chair of the Board, effective March 13. As previously communicated, Tony H...

Analyst ratings

74%

of 23 ratings
Buy
73.9%
Hold
26.1%
Sell
0%

People also own

Based on the portfolios of people who own RGEN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.